Department of Emergency Medicine Archive
-
November 10, 2021
COVID test accuracy appears to vary by time of day
Vanderbilt researchers are examining the effect of time of day on COVID test accuracy. -
November 4, 2021
Study examines long-term benefit of Two-Midnight Rule
Vanderbilt research is raising new questions about the long-term benefit and value of the so-called Medicare “Two-Midnight Rule” implemented in 2013 to reduce costly and potentially unnecessary inpatient hospital admissions -
September 16, 2021
VUMC team to test personalized acute heart failure treatment
Researchers at Vanderbilt have been awarded a five-year, $4 million federal grant to test whether a personalized medicine strategy will improve outcomes for patients hospitalized with acute heart failure. -
September 2, 2021
Barrett named executive medical director of Vanderbilt Emergency Services
Tyler Barrett, MD, MSCI, associate professor of Emergency Medicine, has been named executive medical director of Vanderbilt Emergency Services and Vanderbilt University Adult Emergency Department. -
July 26, 2021
VUMC, NIH launch clinical trial to test novel therapies to protect host tissue against COVID-19
Vanderbilt University Medical Center researchers, supported by the National Institutes of Health (NIH), are leading a nationwide clinical trial to explore the safety and effectiveness of a group of novel drugs designed to protect patients hospitalized with COVID-19 at high risk of poor outcomes. -
May 26, 2021
VUMC researchers receive grant from the National Heart, Lung, and Blood Institute to develop biomarkers to improve the diagnosis of acute heart failure
Researchers at Vanderbilt University Medical Center (VUMC) have received a four-year, $6.2-million grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health to develop a novel panel of biomarkers to improve the diagnosis of acute heart failure (AHF). -
May 6, 2021
VUMC to lead national study to treat severe COVID complications
The Vanderbilt Institute for Clinical and Translational Research (VICTR) has been awarded a major federal grant to lead a national trial of treatments targeting the Renin Angiotensin Aldosterone System (RAAS) in patients hospitalized with COVID-19.